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Abstract 
With increasing prevalence of methicillin resistant
Staphylococcus aureus in clinical settings and injudicious
use of antibiotics, resistance among MRSA against
commonly used antibiotics is increasing. To assess the
susceptibility pattern of MRSA against vancomycin,
linezolid, tigecycline, rifampicin, fosfomycin fusidic acid,
clindamycin, trimethoprim-sulfamethoxazole and
teicoplanin, minimum inhibitory concentrations (MICs)
for given antimicrobials were performed on 234 MRSA
clinical isolates using automated VITEK 2 system.
Vancomycin, linezolid, rifampicin, clindamycin, co-
trimoxazole and teicoplanin susceptibilities were
interpreted according to CLSI breakpoints, while
tigecycline, fosfomycin and fusidic acid were interpreted
according to BSAC breakpoints. All isolates were found
susceptible to vancomycin, tigecycline, teicoplanin and
linezolid. Non-susceptibility of the isolates for rifampicin,
fusidic acid and fosfomycin was noted for 58(25%). Co-
trimoxazole and clindamycin were found less susceptible
showing high resistance rates of 61.5% and 42.3%,
respectively. Vancomycin resistance was not found,
however an increased MIC of 1 µg/ml was observed in
about 25% of clinical strains. Increase in vancomycin MICs
in MRSA is of concern and alternative antimicrobial
options must be evaluated and considered for treatment
of MRSA infections. Continuous antimicrobial surveillance
is needed to monitor resistance patterns and detect
possible emergence of vancomycin non-susceptible
isolates. 
Keywords: MRSA, Staphyloccoccus aureus, minimum
inhibitory concentration, MIC, vancomycin susceptibility
Introduction
Staphylococcus aureus is a significant healthcare threat in
both community and hospital settings. Antimicrobial
choices against S. aureus are getting limited as it
continues to develop resistance to a range of
antimicrobial agents. In the recent past, prevalence of
methicillin resistant S. aureus (MRSA) strains has increased
worldwide. According to available literature from
Pakistan, its frequency of isolation from human infections
ranges from 20-50%.1,2
Most of MRSA are also resistant to common anti-
staphylococcal drugs such as aminoglycosides,
fluoroquinolones, tetracycline, trimethoprim-
sulfamethoxazole, macrolide-lincosamides.3 For such
strains, vancomycin is considered as a drug of choice,
however high cost, toxicity and poor tissue penetration,
especially in the lungs, bone and CNS remains an issue
with its use. Additionally, emergence of vancomycin
resistant and vancomycin intermediate S. aureus (VRSA &
VISA) strains, in different parts of the world, including
Pakistan is a matter of concern.4 These issues have led to
limited number of available therapeutic options against
MRSA.
There is a need to explore alternative drugs that can be
used to treat MRSA and probable VRSA infections in
future. Antibiotics such as linezolid, tigecycline,
rifampicin, fosfomycin and fusidic acid have been proved
effective for MRSA infections internationally, but there is
limited data regarding their efficacy in local clinical
isolates. Therefore, this study aimed to assess the drug
resistance against vancomycin, linezolid, tigecycline,
rifampicin, fosfomycin, fusidic acid, clindamycin,
trimethoprim-sulfamethoxazole and teicoplanin so as to
guide for alternative therapeutic options to the
physicians for the empirical as well as targeted use.
Methods and Results
This cross sectional study was conducted at the clinical
microbiology laboratory of Aga Khan University Hospital
(AKUH). The AKUH is one of the largest tertiary care
hospitals in Pakistan and its laboratory has a network of
more than 200 collection units through which it caters
inpatients as well as outpatients countrywide. Exemption
for ethical approval was granted by Ethical Research
Committee of the Aga Khan University (3209-Pat-ERC-14).
For this study, a total of 234 clinical isolates of S. aureus were
included from period of May 2013 to April 2014. Duplicate
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samples from the same patient were excluded. All isolates
were identified by colony morphology, gram staining,
catalase, coagulase and DNase test. Methicillin resistance
was detected by taking cefoxitin as a surrogate marker and
was interpreted according to Clinical Laboratory Standard
Institute (CLSI) breakpoints.5 Cefoxitin was interpreted
sensitive at (mimimum inhibitory concentration) MIC <4
µg/ml and resistant at MIC >8 µg/ml. Following the
identification of MRSA, susceptibility testing was performed
against vancomycin, linezolid, tigecycline, fosfomycin,
rifampicin, fusidic acid, clindamycin, trimethoprim-
sulfamethoxazole and teicoplanin was performed using
automated VITEK 2 system (bioMe´rieux, France).
Vancomycin, linezolid, rifampicin, clindamycin, trimethoprim
sulfamethoxazole and teicoplanin were interpreted
according to CLSI breakpoints.5
Due to unavailability of clinical
breakpoints for tigecycline,
fosfomycin and fusidic acid in
CLSI, susceptibilities were
interpreted according to BSAC.6
The demographic and
susceptibility data for study
isolates was entered in
Microsoft excel software. MIC50
and MIC90 were calculated for
each tested antibiotic. Majority
of the isolates were from pus
(73.5%) and tissue (7.6%),
followed by respiratory tract
(7.6%) and blood (7.2%). In all
61% of isolates were from
clinical samples of female
patients while 39% were from
male patients. Mean age of the
patients was 35.5±21.54 years.
Most of clinical specimens were
from Karachi and interior Sindh
(Figure). Overall, isolates showed varied susceptibilities
to the tested antibiotics (Table). All isolates were
susceptible to vancomycin, tigecycline, teicoplanin and
linezolid. Non susceptibility of MRSA isolates for
rifampicin, fusidic acid and fosfomycin was found to be
less than 25%. Commonly used antimicrobials like co-
trimoxazole and clindamycin were found less susceptible
showing high resistance rates of 61.5% and 42.3%
respectively. Fortunately, vancomycin resistance was not
seen, however an increased MIC of 1 µg/ml was observed
in about 25% (58/234) of clinical strains.
Discussion and Conclusion
In this study, though all isolates were found susceptible
to vancomycin, its rising MIC is a cause of concern.
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Table: Minimum Inhibitory Concentration of various antimicrobials for MRSA isolates (n =234) during the study period May 2013 to April 2014.
Antibiotic Tested                                        MIC breakpoint (ug/mL)                                MIC range (ug/mL)           MIC50                MIC90                  S (%)                     I (%)                     R (%)
                                                               S                                     I                                R
Clindamycin                                    <0.5                               1-2                             >4                              <0.25 - >8                        1.5                         2                         57.6                           -                           42.3
Vancomycin                                      <2                                 4-8                           >16                              <0.5 - >2                           1                           1                         100                           -                               -
Linezolid                                             <4                                N/A                            >8                                 <0.5 - 4                            2                           2                         100                           -                               -
Rifampicin                                         <1                                N/A                            >4                              <0.5 - >32                        0.5                        0.5                       87.1                         2.9                          9.8
Co-trimoxazole                               <40                               N/A                           >80                            <10 - >320                        80                        160                      38.4                           -                           61.5
Teicoplanin                                        <8                                  16                            >32                               < 0.5 - 4                            2                           4                         100                           -                               -
Tigecycline                                       <0.5                               N/A                          >0.5                            <0.12 - 0.5                       0.25                      0.5                        100                           -                               -
Fosfomycin                                       <32                               N/A                           >32                              <8 - >128                         64                         64                        79.4                                                        20.5
Fusidic acid                                        <1                                N/A                            >1                              <0.5 - >32                          8                          16                        77.3                       19.6                         2.9
MRSA: Methicillin-resistant Staphylococcus aureus
Figure: Geographic distribution of MRSA isolates.
Increase in vancomycin MICs for MRSA is also reported
from different parts of the world. In 2011, Kaleem et al.,7
reported 46% of MRSA isolates to have an MIC of
>1µg/ml. High vancomycin MICs have been associated
with poor clinical outcomes, shown by  Lodise et al.8 in
his study where 71% patients with MRSA bacteremia
had vancomycin MICs of >1.5 µg/ml and these patients
had a 2.4-fold increase in therapeutic failure compared
to patients with MRSA isolates having vancomycin MICs
of <1.0 µg/ml. Hidayat et al.9 also found that despite
achieving target trough concentration, patients with
MRSA pneumonia and bacteraemia due to strains with
higher MICs of >2 µg/ml had  a poor treatment
response. 
In this study, we did not find resistance against linezolid,
teicoplanin and tigecycline. These antibiotics are
important especially in situations where its use is limited
due to increased MICs, accessibility, bioavailability,
toxicity or cost. Our findings in this regard are concordant
with various studies published locally. Linezolid has been
reported fully susceptible in MRSA isolates by Khalid et al.
and Hannan et al.10,11 Linezolid is cost effective and is
available in oral and parenteral formulations which make
it a viable option for the treatment of MRSA infections.
Teicoplanin can also be used in a wide variety of gram
positive infections such as septicaemia, endocarditis, skin
and soft tissue infections. Moreover, its once daily dosing
reassures good compliance during treatment of serious
MRSA infections. Similarly, tigecycline is also an effective
antibiotic for treatment of serious MRSA infections.
However, use of these antibiotics must be conserved for
serious cases only.
As per our findings, rifampicin, fosfomycin and fusidic
acid have variable susceptibilities against MRSA isolates.
Although proportion of fully resistant MRSA strains
against fusidic acid is low, intermediate resistance of
19% strains to fusidic acid is alarming. Most probable
reason for this development is the excessive use of this
drug as skin ointment and its use as monotherapeutic
agent. Although, rifampicin is a first line anti-
tuberculous drug and is widely used in TB endemic area
like Pakistan, its resistance remained low in study
isolates. Comparable to our results, studies  conducted
by Bukhari et al. and Perveen et al showed 5%  and 10%
resistance to rifampicin, respectively.12,13 Fosfomycin
has a broad spectrum coverage ranging from MRSA, VRE
and MDR gram negative rods. A review article evaluating
the role of fosfomycin against MRSA isolates showed a
susceptibility of approximately 80%, which makes
fosfomycin a viable option for infections which are not
responding to conventional therapy.14 Unfortunately,
around 61% isolates were found resistant to commonly
used antimicrobials like co-trimoxazole and clindamycin
therefore these antimicrobials cannot be used
empirically until susceptibilities are confirmed. These
antimicrobials are particularly useful in clinical scenarios
where cost, bioavailability or accessibility of newer
drugs is an issue. 
A similar study was conducted in Lahore in 2013, where
susceptibility of quinopristin/dalfoprisitin, linezolid and
vancomycin for 50 MRSA isolates was evaluated.15 In this
study, all isolates showed 100% susceptibilities to above
tested antimicrobials. However, their study had lower
sample size and evaluated lesser number of
antimicrobials. The strength of this study is the larger
number of isolates and the use of Vitek 2 system to detect
MICs. Limitation of this study is that a large proportion of
samples are collected outside the hospital, so clinical data
is not available in many cases due to which clinical
outcomes could not be evaluated. Second limitation is
that majority of specimens were from Karachi and interior
Sindh, due to the presence of greater number of
laboratory collection units in the given areas, so the data
is not representative of entire country. 
To conclude, vancomycin remains the drug of choice for
the treatment of serious MRSA infections, however,
emergence of clinical isolates with reduced susceptibility
is worrisome. It is encouraging that current MRSA isolates
are fully susceptible to linezolid, teicoplanin and
tigecycline, and in situations where vancomycin is
contraindicated one can use these drugs safely. Our
findings also show that empirical use of erythromycin,
clindamycin, co-trimoxazole and fusidic acid for
treatment of MRSA infections should not be undertaken
and prior antimicrobial susceptibilities are a must before
initiating therapy with any of these options. Finally, our
findings point towards the need of establishment of
continuous drug surveillance mechanism to detect
development of antimicrobial resistance against MRSA
and possible emergence of VISA and VRSA strains in
future.
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